Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Physiologically-based pharmacokinetic modelling of a CYP2C19 substrate, BMS-823778, utilizing pharmacogenetic data.

Gong J, Iacono L, Iyer RA, Humphreys WG, Zheng M.

Br J Clin Pharmacol. 2018 Jun;84(6):1335-1345. doi: 10.1111/bcp.13565. Epub 2018 Apr 10.

PMID:
29469197
2.

Diclofenac and Its Acyl Glucuronide: Determination of In Vivo Exposure in Human Subjects and Characterization as Human Drug Transporter Substrates In Vitro.

Zhang Y, Han YH, Putluru SP, Matta MK, Kole P, Mandlekar S, Furlong MT, Liu T, Iyer RA, Marathe P, Yang Z, Lai Y, Rodrigues AD.

Drug Metab Dispos. 2016 Mar;44(3):320-8. doi: 10.1124/dmd.115.066944. Epub 2015 Dec 29.

PMID:
26714763
3.

Current Approaches for Absorption, Distribution, Metabolism, and Excretion Characterization of Antibody-Drug Conjugates: An Industry White Paper.

Kraynov E, Kamath AV, Walles M, Tarcsa E, Deslandes A, Iyer RA, Datta-Mannan A, Sriraman P, Bairlein M, Yang JJ, Barfield M, Xiao G, Escandon E, Wang W, Rock DA, Chemuturi NV, Moore DJ.

Drug Metab Dispos. 2016 May;44(5):617-23. doi: 10.1124/dmd.115.068049. Epub 2015 Dec 15. Review.

PMID:
26669328
4.

Characterization of ADME properties of [(14)C]asunaprevir (BMS-650032) in humans.

Gong J, Eley T, He B, Arora V, Philip T, Jiang H, Easter J, Humphreys WG, Iyer RA, Li W.

Xenobiotica. 2016;46(1):52-64. doi: 10.3109/00498254.2015.1048487. Epub 2015 Jul 7.

PMID:
26153443
5.

Quantitative analysis of polyethylene glycol (PEG) and PEGylated proteins in animal tissues by LC-MS/MS coupled with in-source CID.

Gong J, Gu X, Achanzar WE, Chadwick KD, Gan J, Brock BJ, Kishnani NS, Humphreys WG, Iyer RA.

Anal Chem. 2014 Aug 5;86(15):7642-9. doi: 10.1021/ac501507g. Epub 2014 Jul 8.

PMID:
25003239
6.

Metabolic chiral inversion of brivanib and its relevance to safety and pharmacology.

Gong J, Gan J, Masson E, Syed S, Xia YQ, Williams D, Pursley J, Jemal M, Humphreys WG, Iyer RA.

Drug Metab Dispos. 2012 Dec;40(12):2374-80. doi: 10.1124/dmd.112.047340. Epub 2012 Sep 14.

PMID:
22983304
7.

Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.

Su H, Boulton DW, Barros A Jr, Wang L, Cao K, Bonacorsi SJ Jr, Iyer RA, Humphreys WG, Christopher LJ.

Drug Metab Dispos. 2012 Jul;40(7):1345-56. doi: 10.1124/dmd.112.045450. Epub 2012 Apr 10.

PMID:
22496391
8.

In vitro and in vivo metabolism and pharmacokinetics of BMS-562086, a potent and orally bioavailable corticotropin-releasing factor-1 receptor antagonist.

Zhou L, Dockens RC, Liu-Kreyche P, Grossman SJ, Iyer RA.

Drug Metab Dispos. 2012 Jun;40(6):1093-103. doi: 10.1124/dmd.111.043596. Epub 2012 Mar 1.

PMID:
22381334
9.

Identification of the oxidative and conjugative enzymes involved in the biotransformation of brivanib.

Gong J, Gan J, Iyer RA.

Drug Metab Dispos. 2012 Jan;40(1):219-26. doi: 10.1124/dmd.111.042457. Epub 2011 Oct 11.

PMID:
21989950
10.

In vitro characterization of the metabolic pathways and cytochrome P450 inhibition and induction potential of BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor.

Hong H, Su H, Ma L, Yao M, Iyer RA, Humphreys WG, Christopher LJ.

Drug Metab Dispos. 2011 Sep;39(9):1658-67. doi: 10.1124/dmd.111.039776. Epub 2011 Jun 14.

PMID:
21673131
11.

Metabolism and disposition of [14C]brivanib alaninate after oral administration to rats, monkeys, and humans.

Gong J, Gan J, Caceres-Cortes J, Christopher LJ, Arora V, Masson E, Williams D, Pursley J, Allentoff A, Lago M, Tran SB, Iyer RA.

Drug Metab Dispos. 2011 May;39(5):891-903. doi: 10.1124/dmd.110.037341. Epub 2011 Feb 2.

PMID:
21289073
12.

Metabolism of [2-14C]p-hydroxyphenyl acetic acid in rat, monkey and human hepatocytes and in bile-duct cannulated rats.

Zhou L, Liu-Kreyche P, Iyer RA.

Xenobiotica. 2011 Apr;41(4):312-9. doi: 10.3109/00498254.2010.540681. Epub 2010 Dec 14.

PMID:
21143006
13.

Mechanistic studies on a P450-mediated rearrangement of BMS-690514: conversion of a pyrrolotriazine to a hydroxypyridotriazine.

Hong H, Caceres-Cortes J, Su H, Huang X, Roongta V, Bonacorsi S Jr, Hong Y, Tian Y, Iyer RA, Humphreys WG, Christopher LJ.

Chem Res Toxicol. 2011 Jan 14;24(1):125-34. doi: 10.1021/tx100337s. Epub 2010 Nov 16.

PMID:
21080678
14.

Metabolism and disposition of [14C]BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor, after oral administration to humans.

Christopher LJ, Hong H, Vakkalagadda BJ, Clemens PL, Su H, Roongta V, Allentoff A, Sun H, Heller K, Harbison CT, Iyer RA, Humphreys WG, Wong T, Zhang S.

Drug Metab Dispos. 2010 Nov;38(11):2049-59. doi: 10.1124/dmd.110.034850. Epub 2010 Jul 28.

PMID:
20668249
15.

Metabolism and disposition of [14C]BMS-690514 after oral administration to rats, rabbits, and dogs.

Hong H, Su H, Sun H, Allentoff A, Ekhato IV, Chando T, Caceres-Cortes J, Roongta V, Iyer RA, Humphreys WG, Christopher LJ.

Drug Metab Dispos. 2010 Jul;38(7):1189-201. doi: 10.1124/dmd.110.032755. Epub 2010 Apr 2.

PMID:
20363952
16.

Disposition of [1'-(14)C]stavudine after oral administration to humans.

Zhou L, Kaul S, Liu-Kreyche P, Tran SB, Espina RR, Warrack BM, Roongta VA, Iyer RA.

Drug Metab Dispos. 2010 Apr;38(4):655-66. doi: 10.1124/dmd.109.030239. Epub 2010 Jan 6.

PMID:
20053818
17.

Lacteal secretion, fetal and maternal tissue distribution of dasatinib in rats.

He K, Lago MW, Iyer RA, Shyu WC, Humphreys WG, Christopher LJ.

Drug Metab Dispos. 2008 Dec;36(12):2564-70. doi: 10.1124/dmd.108.022764. Epub 2008 Sep 11.

PMID:
18787054
18.

Biotransformation of [14C]dasatinib: in vitro studies in rat, monkey, and human and disposition after administration to rats and monkeys.

Christopher LJ, Cui D, Li W, Barros A Jr, Arora VK, Zhang H, Wang L, Zhang D, Manning JA, He K, Fletcher AM, Ogan M, Lago M, Bonacorsi SJ, Humphreys WG, Iyer RA.

Drug Metab Dispos. 2008 Jul;36(7):1341-56. doi: 10.1124/dmd.107.018234. Epub 2008 Apr 17.

PMID:
18420785
19.

Metabolism and disposition of dasatinib after oral administration to humans.

Christopher LJ, Cui D, Wu C, Luo R, Manning JA, Bonacorsi SJ, Lago M, Allentoff A, Lee FY, McCann B, Galbraith S, Reitberg DP, He K, Barros A Jr, Blackwood-Chirchir A, Humphreys WG, Iyer RA.

Drug Metab Dispos. 2008 Jul;36(7):1357-64. doi: 10.1124/dmd.107.018267. Epub 2008 Apr 17.

PMID:
18420784
20.

Metabolism of [14C]gemopatrilat after oral administration to rats, dogs, and humans.

Wait JC, Vaccharajani N, Mitroka J, Jemal M, Khan S, Bonacorsi SJ, Rinehart JK, Iyer RA.

Drug Metab Dispos. 2006 Jun;34(6):961-70. Epub 2006 Mar 15.

PMID:
16540589
21.
22.

Comparative biotransformation of radiolabeled [(14)C]omapatrilat and stable-labeled [(13)C(2)]omapatrilat after oral administration to rats, dogs, and humans.

Iyer RA, Malhotra B, Khan S, Mitroka J, Bonacorsi S Jr, Waller SC, Rinehart JK, Kripalani K.

Drug Metab Dispos. 2003 Jan;31(1):67-75.

PMID:
12485955
23.

Oral bioavailability and disposition of [14C]omapatrilat in healthy subjects.

Malhotra BK, Iyer RA, Soucek KM, Behr D, Liao WC, Mitroka JG, Kaul S, Cohen MB, Knupp CA.

J Clin Pharmacol. 2001 Aug;41(8):833-41.

PMID:
11504270
24.

Metabolism of [(14)C]omapatrilat, a sulfhydryl-containing vasopeptidase inhibitor in humans.

Iyer RA, Mitroka J, Malhotra B, Bonacorsi S Jr, Waller SC, Rinehart JK, Roongta VA, Kripalani K.

Drug Metab Dispos. 2001 Jan;29(1):60-9.

PMID:
11124231
25.

Bioactivation mechanisms of haloalkene cysteine S-conjugates modeled by gas-phase, ion-molecule reactions.

Luu NC, Iyer RA, Anders MW, Ridge DP.

Chem Res Toxicol. 2000 Jul;13(7):610-5.

PMID:
10898593
26.
28.

Cyclic hydroxamic acid inhibitors of prostate cancer cell growth: selectivity and structure activity relationships.

Roberts KP, Iyer RA, Prasad G, Liu LT, Lind RE, Hanna PE.

Prostate. 1998 Feb 1;34(2):92-9.

PMID:
9465940
31.

Supplemental Content

Support Center